Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly utilized in the management of leukemia across multiple subtypes. Graft versus leukemia (GVL) is a critical component of successful transplantation and involves donor cells eradicating residual leukemia within the recipient. Graft versus host disease (GVHD) by contrast is a common complication of the transplantation process in which donor cells identify the recipient's various organ systems as foreign, thereby leading to a multitude of organ toxicities that can be described as autoimmune in nature. As both GVL and GVHD are mediated by a similar mechanism, these processes are felt to occur in tandem with one another. Here, we review the allogeneic HCT process in the context of GVL.

异基因造血干细胞移植（HSCT）通常用于治疗多种亚型的白血病。移植物抗白血病（GVL）是成功移植的关键组成部分，涉及供体细胞根除受者体内残留的白血病。相比之下，移植物抗宿主病（GVHD）是移植过程中常见的并发症，其中供体细胞将受体的各种器官系统识别为外源，从而导致多种器官毒性，本质上可以被描述为自身免疫性的。由于 GVL 和 GVHD 都是由相似的机制介导的，因此这些过程被认为是同时发生的。在这里，我们回顾 GVL 背景下的同种异体 HCT 过程。